Hello again, Sorry to inundate your inbox but I need to make an important correction to today’s post regarding MAPS’ Phase 3 trial. Michael Haichin pointed out the error in the comments: “To clarify, MAPS is required to run 2 x 100-person phase 3 trials. Interim analysis confirmed they didn't need to enroll more than 100 people for that first trial (and due to COVID, FDA offered to end early with only 90 subjects). Another phase 3 trial (MAPP2) of 100 people is still needed, so unfortunately there are no savings on time or money.”
We sent an email to with a link to finish logging in.